Related Experiment Videos
[Thorotrast-related hepatosis]
A Martí Vicente1, P González Carro, J Enríquez
1Escuela de Patología Digestiva, Hospital de la Santa Creu i Sant Pau, Barcelona.
Revista Espanola De Enfermedades Digestivas
|January 1, 1993
Summary
Thorotrast, a contrast agent, can cause liver disease, including fibrosis, nodularity, and cancer. Laparoscopy is a valuable diagnostic tool for identifying these Thorotrast-induced liver changes.
Area of Science:
- Hepatology
- Radiology
- Oncology
Background:
- Thorotrast (thorium dioxide) was historically used as a radiocontrast agent.
- Its long-term retention in the liver can lead to chronic toxicity and disease.
- Understanding the spectrum of Thorotrast-induced liver disease is crucial for patient management.
Observation:
- Clinical, pathological, and laparoscopic data from five patients with liver disease were analyzed.
- Laparoscopic examination revealed varying degrees of hepatic fibrosis and nodularity.
- Biopsies indicated precancerous changes like dysplasia in some patients.
Findings:
- Laparoscopy demonstrated characteristic signs of liver damage consistent with Thorotrast exposure.
- One patient was diagnosed with cholangiocarcinoma, a bile duct cancer.
- Two patients exhibited dysplasia, a precursor to cancer, on liver biopsy.
Implications:
- The laparoscopic appearance of Thorotrast-induced liver disease is highly suggestive, aiding diagnosis.
- Early detection of dysplasia and cancer is critical for improved patient outcomes.
- This study highlights the enduring risks associated with historical Thorotrast use.